AI Analysis
AI-generated analysis. Always verify with the original filing.
Purple Biotech Ltd. filed a March 2026 corporate presentation as Exhibit 99.1, highlighting the CAPTN-3 platform with lead tri-specific antibody IM1240 entering preclinical toxicology studies in 2026, IND submission, and Phase 1 initiation in 2027, alongside clinical-stage assets CM24 and NT219 available for partnering.
Key Takeaways
1Cash $9.5M as of December 31, 2025 with runway into H1 2027 covering IM1240 tox, IND, and Phase 1 initiation
2930K shares outstanding as of December 31, 2025
3IM1240 (capped-CD3x5T4xNKG2A) GLP tox complete Q3 2026, IND submission Q4 2026, Phase 1 start Q1 2027
4NT219 Phase 2 head and neck interim data expected 2026
5CM24 Phase 2 in pancreatic cancer available for partnering
6IM1305 (capped-CD3xTROP2xNKG2A) preclinical advancement ongoing